Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new study by Drs William Watson and Perry Green has found that the heart can increase its use of fat as well as glucose as fuel on demand, even in patients where the heart is failing. Moreover, using fat leads to increased energy production, and a stronger heartbeat. These findings, published in the journal Circulation, run counter to the traditional view that the reason hearts fail is because of an inability to switch between glucose and fat when needed.

Heart failure is a condition that affects nearly a million people in the United Kingdom alone. “Treatments for heart failure usually includes blood pressure medications and water tablets, to reduce the strain on the heart,” said Dr Watson. “But effective medications to actually improve the pumping strength of the heart have so far remained elusive.”  Researchers have tried for decades to increase the heart's glucose usage to achieve this but with little success. So doctoral students William Watson and Perry Green took a different track. 

They focussed on fat in a complex piece of research that involved 35 volunteers and experiments both in a state-of-the-art MRI scanner and during pacemaker implantation when measurements of flow and pressure could be taken alongside blood sampling from within the heart.  This allowed the researchers to track the heart’s function and how it used and produced energy when patients with heart failure were given either a mixture of insulin and glucose, or a mixture of fats, directly into the bloodstream. Much to their surprise, the team found that the heart’s energy use and pumping action was better after the fat infusion, rather than the insulin and glucose mixture.

Dr Green said “The results challenge the glucose-centric direction of this field of research over the last half century.” The research team now think that strategies promoting fat metabolism could potentially form the basis for future therapies for heart failure.

The research was led by a collaboration between Consultant Cardiologists Professor Oliver Rider in the Oxford Centre for Clinical Magnetic Resonance Research (OCMR) and Professor Neil Herring in the Department of Physiology, Anatomy and Genetics (DPAG),and was supported by the British Heart Foundation.

Professor Herring said “Although this is early days, we think that these results set an exciting new direction for this field”. Professor Rider added “This research has answered a major question in heart failure research and has the potential to translate into beneficial new medications for patients in the future.”

Read the full paper.

 

 

Similar stories

Researchers highlight need for better sleep support for NHS shift workers

A new study led by researchers at the University of Oxford’s Radcliffe Department of Medicine, has found that many NHS staff working shifts experience sleep difficulties, with researchers calling for more accessible, evidence-based support to help staff manage sleep.

Oxford spin-out raises $90 million to advance new treatments for blood cancers

Alethio Therapeutics, a University of Oxford spin-out co-founded by Professors Adam Mead and Beth Psaila, has secured $90 million (£67 million) in oversubscribed Series A financing to develop a new generation of therapies for myeloproliferative neoplasms (MPNs).

Breakthrough in non-invasive liver testing

Two major international studies, including an imaging study led by researchers from the Radcliffe Department of Medicine, have provided new evidence on which non-invasive tests can accurately diagnose and measure the severity of metabolic dysfunction-associated steatotic liver disease (MASLD) and its more severe form, MASH, potentially reducing reliance on liver biopsy.

Oxford-led research identifies a new therapeutic strategy to reverse established atrial fibrosis in atrial fibrillation

Researchers at the University of Oxford have identified a promising new RNA-based therapeutic approach that can reverse established atrial fibrosis. Atrial fibrosis is a major contributor to atrial fibrillation, the most common sustained cardiac arrhythmia worldwide.

Therapy Acceleration Lab achieves Medical Laboratory Accreditation

The Therapy Acceleration Lab (TAL) at the MRC WIMM has been accredited by the United Kingdom Accreditation Service (UKAS) to ISO 15189:2022 – Medical laboratories – Requirements for quality and competence.

Gene editing points to new treatment approach for inherited blood disorder

Researchers at the MRC Weatherall Institute of Molecular Medicine have used genome editing to reactivate an embryonic globin gene, offering a potential new strategy for treating severe α-thalassaemia.

Similar stories

Researchers highlight need for better sleep support for NHS shift workers

A new study led by researchers at the University of Oxford’s Radcliffe Department of Medicine, has found that many NHS staff working shifts experience sleep difficulties, with researchers calling for more accessible, evidence-based support to help staff manage sleep.

Oxford spin-out raises $90 million to advance new treatments for blood cancers

Alethio Therapeutics, a University of Oxford spin-out co-founded by Professors Adam Mead and Beth Psaila, has secured $90 million (£67 million) in oversubscribed Series A financing to develop a new generation of therapies for myeloproliferative neoplasms (MPNs).

Breakthrough in non-invasive liver testing

Two major international studies, including an imaging study led by researchers from the Radcliffe Department of Medicine, have provided new evidence on which non-invasive tests can accurately diagnose and measure the severity of metabolic dysfunction-associated steatotic liver disease (MASLD) and its more severe form, MASH, potentially reducing reliance on liver biopsy.

Oxford-led research identifies a new therapeutic strategy to reverse established atrial fibrosis in atrial fibrillation

Researchers at the University of Oxford have identified a promising new RNA-based therapeutic approach that can reverse established atrial fibrosis. Atrial fibrosis is a major contributor to atrial fibrillation, the most common sustained cardiac arrhythmia worldwide.

Therapy Acceleration Lab achieves Medical Laboratory Accreditation

The Therapy Acceleration Lab (TAL) at the MRC WIMM has been accredited by the United Kingdom Accreditation Service (UKAS) to ISO 15189:2022 – Medical laboratories – Requirements for quality and competence.

Gene editing points to new treatment approach for inherited blood disorder

Researchers at the MRC Weatherall Institute of Molecular Medicine have used genome editing to reactivate an embryonic globin gene, offering a potential new strategy for treating severe α-thalassaemia.